Lentiviral Gene Therapy with CD34+Hematopoietic Cells for Hemophilia A Reply

被引：0
作者：
Srivastava, Alok [1 ]
Spencer, Trent [2 ]
机构：
[1] St Johns Med Coll Hosp, Bengaluru, India
[2] Emory Univ, Atlanta, GA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2025年 / 392卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1766 / 1766
页数：1
相关论文
共 5 条
[1]   In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process [J].
Golder, Mia ;
Mewburn, Jeffrey ;
Lillicrap, David .
THROMBOSIS AND HAEMOSTASIS, 2013, 109 (01) :53-60
[2]   Diagnosis and treatment challenges in lower resource countries: State-of-the-art [J].
Mahlangu, Johnny ;
Diop, Saliou ;
Lavin, Michelle .
HAEMOPHILIA, 2024, 30 :78-85
[3]  
Montini E, 2025, MOL THER, V33, P6, DOI 10.1016/j.ymthe.2024.12.028
[4]   The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B [J].
Soucie, J. Michael ;
Monahan, Paul E. ;
Kulkarni, Roshni ;
Konkle, Barbara A. ;
Mazepa, Marshall A. .
BLOOD ADVANCES, 2018, 2 (16) :2136-2144
[5]   Development of the First World Health Organization Lentiviral Vector Standard: Toward the Production Control and Standardization of Lentivirus-Based Gene Therapy Products [J].
Zhao, Yuan ;
Stepto, Hannah ;
Schneider, Christian K. .
HUMAN GENE THERAPY METHODS, 2017, 28 (04) :205-214
1